Cargando…

Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney

Nano-scale secondary ion mass spectrometry (NanoSIMS) enables trace element and isotope analyses with high spatial resolution. This unique capability has recently been exploited in several studies analyzing the subcellular distribution of Au and Pt anticancer compounds. However, these studies were r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Legin, A. A., Theiner, S., Schintlmeister, A., Reipert, S., Heffeter, P., Jakupec, M. A., Mayr, J., Varbanov, H. P., Kowol, C. R., Galanski, M. S., Berger, W., Wagner, M., Keppler, B. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society of Chemistry 2016
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004953/ https://www.ncbi.nlm.nih.gov/pubmed/29997796 http://dx.doi.org/10.1039/c5sc04383b

Ejemplares similares

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs
por: Legin, Anton A., et al.
Publicado: (2014)

Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin
por: Varbanov, Hristo, et al.
Publicado: (2011)

Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect
por: Legin, Anton A., et al.
Publicado: (2020)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Theoretical Investigations and Density Functional Theory Based Quantitative Structure–Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes
por: Varbanov, Hristo P., et al.
Publicado: (2012)

Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation†
por: Schreiber-Brynzak, Ekaterina, et al.
Publicado: (2016)

Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment?
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Diamminetetrakis(carboxylato)platinum(IV) Complexes – Synthesis, Characterization, and Cytotoxicity
por: Hoffmeister, Björn R, et al.
Publicado: (2012)

EGFR-targeting peptide-coupled platinum(IV) complexes
por: Mayr, Josef, et al.
Publicado: (2017)

Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD‐100/KP1339 in the Endoplasmic Reticulum
por: Neuditschko, Benjamin, et al.
Publicado: (2021)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Synthesis and Characterization of New Ethylenediamine Platinum(IV) Complexes Containing Lipophilic Carboxylate Ligands
por: Galanski, M., et al.
Publicado: (1995)

Synthesis and in vitro Antitumor Potency of (Cyclohexane-1,2-Diamine)Platinum(II) Complexes with Aminotris(Methylenephosphonic Acid) as Bone-Seeking Ligand
por: Galanski, Markus, et al.
Publicado: (2005)

NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
por: Trondl, Robert, et al.
Publicado: (2012)

Guanidine platinum(II) complexes: synthesis, in vitro antitumor activity, and DNA interactions()
por: Legin, Anton A., et al.
Publicado: (2014)

The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
por: Berasaluce, Iker, et al.
Publicado: (2019)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

Quaternary Ammonium Palmitoyl Glycol Chitosan (GCPQ) Loaded with Platinum-Based Anticancer Agents—A Novel Polymer Formulation for Anticancer Therapy
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018)

A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt(IV) Complexes under Physiological Conditions
por: Kastner, Alexander, et al.
Publicado: (2019)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes
por: Hanif, Muhammad, et al.
Publicado: (2013)

Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity
por: Büchel, Gabriel E., et al.
Publicado: (2012)

Impact of Stepwise NH(2)-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention
por: Kowol, Christian R., et al.
Publicado: (2016)

Human serum albumin as a copper source for anticancer thiosemicarbazones
por: Schaier, Martin, et al.
Publicado: (2023)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Metal–Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation
por: Filak, Lukas K., et al.
Publicado: (2013)

Potential Anticancer Activities and Catalytic Oxidation Efficiency of Platinum(IV) Complex
por: El-bendary, Mohamed M., et al.
Publicado: (2022)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

α-N-Heterocyclic thiosemicarbazones induce ER stress-mediated CHOP activation
por: Trondl, Robert, et al.
Publicado: (2010)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy
por: Filak, Lukas K., et al.
Publicado: (2010)

Oxaliplatin reacts with DMSO only in the presence of water
por: Varbanov, Hristo P., et al.
Publicado: (2017)

In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
por: Olszewski, Ulrike, et al.
Publicado: (2009)

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes
por: Shi, Huayun, et al.
Publicado: (2020)

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
por: Heffeter, Petra, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k6vkkirlt86qraucemj5s9egsq